Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

ClinicalTrials.gov ID: NCT00277498

Public ClinicalTrials.gov record NCT00277498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Study identification

NCT ID
NCT00277498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
528 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2005
Primary completion
Not listed
Completion
May 31, 2007
Last update posted
Feb 17, 2021

2005 – 2007

United States locations

U.S. sites
64
U.S. states
27
U.S. cities
55
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35216
Pfizer Investigational Site Flagstaff Arizona 86001
Pfizer Investigational Site Artesia California 90701
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Newport Beach California 92663
Pfizer Investigational Site Sacramento California 95815
Pfizer Investigational Site San Francisco California 94105
Pfizer Investigational Site Colorado Springs Colorado 80907
Pfizer Investigational Site Gainesville Florida 32605
Pfizer Investigational Site Lecanto Florida 34461
Pfizer Investigational Site Miami Florida 33136
Pfizer Investigational Site Panama City Florida 32405
Pfizer Investigational Site Idaho Falls Idaho 83404
Pfizer Investigational Site Bourbonnais Illinois 60914
Pfizer Investigational Site Calumet City Illinois 60409
Pfizer Investigational Site Chicago Illinois 60611
Pfizer Investigational Site Chicago Illinois 60617
Pfizer Investigational Site Evansville Indiana 47713
Pfizer Investigational Site Madison Indiana 47250
Pfizer Investigational Site New Albany Indiana 47150
Pfizer Investigational Site Newburgh Indiana 47630
Pfizer Investigational Site Iowa City Iowa 52245
Pfizer Investigational Site Wichita Kansas 67208
Pfizer Investigational Site Louisville Kentucky 40217
Pfizer Investigational Site Bangor Maine 04401
Pfizer Investigational Site Reading Massachusetts 01867
Pfizer Investigational Site Ann Arbor Michigan 48105
Pfizer Investigational Site Detroit Michigan 48201-1423
Pfizer Investigational Site Stillwater Minnesota 55082
Pfizer Investigational Site Creve Coeur Missouri 63141-6846
Pfizer Investigational Site Kansas City Missouri 64114
Pfizer Investigational Site Warrensburg Missouri 64093
Pfizer Investigational Site Washington Missouri 63090
Pfizer Investigational Site Piscataway New Jersey 08854-4143
Pfizer Investigational Site Princeton New Jersey 08540-3211
Pfizer Investigational Site Brooklyn New York 11215
Pfizer Investigational Site New York New York 10032-3701
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Durham North Carolina 27704-2122
Pfizer Investigational Site Durham North Carolina 27710
Pfizer Investigational Site Greensboro North Carolina 27408-7022
Pfizer Investigational Site Winston-Salem North Carolina 27101
Pfizer Investigational Site Cleveland Ohio 44115-3176
Pfizer Investigational Site Roseburg Oregon 97470
Pfizer Investigational Site Philadelphia Pennsylvania 19114
Pfizer Investigational Site Philadelphia Pennsylvania 19148
Pfizer Investigational Site Reading Pennsylvania 19606
Pfizer Investigational Site Wyomissing Pennsylvania 19610
Pfizer Investigational Site Charleston South Carolina 29403
Pfizer Investigational Site Charleston South Carolina 29414
Pfizer Investigational Site Maryville Tennessee 37803
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Austin Texas 78746
Pfizer Investigational Site Dallas Texas 75231-5185
Pfizer Investigational Site El Paso Texas 79902
Pfizer Investigational Site El Paso Texas 79904
Pfizer Investigational Site Fort Worth Texas 76102-4427
Pfizer Investigational Site Houston Texas 77025-1635
Pfizer Investigational Site Houston Texas 77055
Pfizer Investigational Site San Antonio Texas 78205
Pfizer Investigational Site San Antonio Texas 78209
Pfizer Investigational Site San Antonio Texas 78240
Pfizer Investigational Site Fredericksburg Virginia 22405
Pfizer Investigational Site Seattle Washington 98133

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00277498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2021 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00277498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →